Eddy Lee

iX Biopharma will also receive double digit percentage royalties on future net sales of any licensed product.

SINGAPORE (Dec 18): Catalist-listed iX Biopharma has launched a line of nutraceuticals that could help it turn a profit sooner than it could have done through the development of its pain management, erectile dysfunction and opioid treatment drugs. The pro

SINGAPORE (Aug 26): iX Biopharma is a small Catalist-listed Singapore company focusing on a big goal: Developing pain management drugs that are an alternative to opioids, and the optimum system to deliver these drugs into the body.